Shanghai Bao Pharmaceuticals Co., Ltd. logo

Shanghai Bao Pharmaceuticals Co., Ltd.

2659.HK

HKSEHealthcareBiotechnology

最新データ

HK$15.73

−HK$0.36 · -2.24%

8月24日 16:08 HKT

2659.HKの企業概要

日中の時刻はHKTです。市場データは遅延する場合があります。

企業プロフィール

会社ウェブサイト

Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH CTP) for assisted reproduction. The company also develops KJ101, a recombinant human chymotrypsin developed through synthetic biology that is in Phase 2 clinical trials; KJ015, a bispecific anti HER2 antibody; BJ007, a subcutaneous formulation of ceftriaxone sodium for the treatment of bacterial infections; BJ009, a first generation cephalosporin antibiotic for treating bacterial infections, including of the skin, bones, joints, reproductive organs, blood, heart valves, respiratory tract, biliary tract, and urinary tract; and SJ04, a recombinant human chorionic gonadotropin (hCG) that can be used in assisted reproductive procedures to accelerate follicle maturation and induce ovulation. These product candidates are in Phase 1 clinical trials. In addition, it is developing BJ045, a subcutaneously administered anti CD20 antibody; BJ047, a subcutaneously administered anti CD154 antibody; BJ008, a subcutaneous formulation of cefoperazone sodium–sulbactam sodium to treat bacterial infections; and BJ044, a serine protease inhibitor with broad anti inflammatory properties. These product candidates are in the preclinical stage. Further, the company licenses its intellectual property and other deliverables and provides technical services. Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.

業界
Biotechnology
セクター
Healthcare
本社
CN
最高経営責任者(CEO)
Wang Zheng
上場以来
2025年12月10日
従業員
354

市場での位置

日中レンジ

現在 HK$15.73

52週レンジ

現在 HK$15.73

始値
HK$16.12
前日終値
HK$16.09
出来高
20.11万
0.08× 平均
平均出来高
266.66万
1日平均出来高
時価総額
24.02億 HKD
ベータ
0.92
市場参照 1
50日平均
HK$17.9348
平均以下(-12.29%)
200日平均
HK$67.3497
平均以下(-76.64%)

2659.HKの同業他社

2659.HKを保有するETF

この株式へのエクスポージャーを報告している上場投資信託です。

GoAI で研究を続ける

GoAIで2659.HKを調査

research.disclaimer